NASDAQ:RDHL - RedHill Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.08 +0.08 (+1.14 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$7.07
Today's Range$7.07 - $7.16
52-Week Range$4.30 - $11.25
Volume5,345 shs
Average Volume99,463 shs
Market Capitalization$148.91 million
P/E Ratio-2.72
Dividend YieldN/A
Beta0.69

About RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma logoRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions. Its clinical-stage development programs include TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with an ongoing confirmatory Phase III study and successful results from a first Phase III study; RHB-104 with an ongoing first Phase III study for Crohn's disease and a planned pivotal Phase III study for nontuberculous mycobacteria infections; BEKINDA (RHB-102) with positive results from a Phase III study in acute gastroenteritis and gastritis, and positive results from a Phase II study in IBS-D; YELIVA (ABC294640), a SK2 selective inhibitor, targeting multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase IIa study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; and RHB-107 (MESUPRON), a Phase II-stage serine protease inhibitor targeting gastrointestinal and other solid tumor cancers. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Debt-to-Equity RatioN/A
Current Ratio4.20
Quick Ratio4.14

Price-To-Earnings

Trailing P/E Ratio-2.72
Forward P/E Ratio-4.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.01 million
Price / Sales37.55
Cash FlowN/A
Price / CashN/A
Book Value$2.12 per share
Price / Book3.34

Profitability

EPS (Most Recent Fiscal Year)($2.60)
Net Income$-45,540,000.00
Net Margins-726.64%
Return on Equity-114.27%
Return on Assets-86.82%

Miscellaneous

Employees74
Outstanding Shares21,270,000

RedHill Biopharma (NASDAQ:RDHL) Frequently Asked Questions

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd (NASDAQ:RDHL) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.50). The biotechnology company had revenue of $2.45 million for the quarter, compared to analyst estimates of $2.14 million. RedHill Biopharma had a negative return on equity of 114.27% and a negative net margin of 726.64%. View RedHill Biopharma's Earnings History.

When is RedHill Biopharma's next earnings date?

RedHill Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for RedHill Biopharma.

What price target have analysts set for RDHL?

6 brokerages have issued 1 year target prices for RedHill Biopharma's stock. Their forecasts range from $18.00 to $36.00. On average, they expect RedHill Biopharma's stock price to reach $23.25 in the next year. View Analyst Ratings for RedHill Biopharma.

What are Wall Street analysts saying about RedHill Biopharma stock?

Here are some recent quotes from research analysts about RedHill Biopharma stock:
  • 1. According to Zacks Investment Research, "Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). " (5/12/2018)
  • 2. FBR & Co analysts commented, "BeiGene presented updated data at ICML from BTK inhibitor BGB-3111’s clinical." (6/16/2017)

Who are some of RedHill Biopharma's key competitors?

Who are RedHill Biopharma's key executives?

RedHill Biopharma's management team includes the folowing people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 52)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 49)
  • Mr. Gilead Raday, Chief Operating Officer (Age 43)
  • Dr. Reza Fathi, Sr. VP of R&D (Age 63)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 42)

Has RedHill Biopharma been receiving favorable news coverage?

Media coverage about RDHL stock has trended positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. RedHill Biopharma earned a media sentiment score of 0.28 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of RedHill Biopharma?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $7.08.

How big of a company is RedHill Biopharma?

RedHill Biopharma has a market capitalization of $148.91 million and generates $4.01 million in revenue each year. The biotechnology company earns $-45,540,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. RedHill Biopharma employs 74 workers across the globe.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 HA`ARBA`A STREET, TEL AVIV L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131.


MarketBeat Community Rating for RedHill Biopharma (RDHL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about RedHill Biopharma and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

RedHill Biopharma (NASDAQ:RDHL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for RedHill Biopharma in the last 12 months. Their average twelve-month price target is $23.25, suggesting that the stock has a possible upside of 228.39%. The high price target for RDHL is $36.00 and the low price target for RDHL is $18.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.60
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.25$23.25$23.60$25.00
Price Target Upside: 228.39% upside317.41% upside323.70% upside379.85% upside

RedHill Biopharma (NASDAQ:RDHL) Consensus Price Target History

Price Target History for RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma (NASDAQ:RDHL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018HC WainwrightSet Price TargetBuy$36.00HighView Rating Details
1/26/2018NomuraInitiated CoverageBuy$18.00HighView Rating Details
11/14/2017Roth CapitalLower Price TargetBuy$27.00 ➝ $20.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$19.00N/AView Rating Details
9/13/2017UBSInitiated CoverageReduceMediumView Rating Details
6/16/2017FBR & CoReiterated RatingBuyLowView Rating Details
(Data available from 5/21/2016 forward)

Earnings

RedHill Biopharma (NASDAQ:RDHL) Earnings History and Estimates Chart

Earnings by Quarter for RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma (NASDAQ:RDHL) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.46)($0.46)($0.46)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.43)($0.43)($0.43)

RedHill Biopharma (NASDAQ RDHL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018        
5/8/20183/31/2018($0.50)($0.50)$2.14 million$2.45 millionViewN/AView Earnings Details
2/22/2018Q4 2017($0.65)($0.50)$1.89 million$2.00 millionViewListenView Earnings Details
11/13/2017Q3 2017($0.72)($0.90)$1.27 million$1.52 millionViewN/AView Earnings Details
7/25/20176/30/2017($0.58)($0.60)$0.34 million$0.48 millionViewN/AView Earnings Details
5/3/20173/31/2017($0.64)($0.50)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.63)($0.70)$0.10 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.59)($0.70)ViewN/AView Earnings Details
7/27/2016Q116($0.58)($0.06)ViewListenView Earnings Details
4/20/2016Q1 2016($0.48)($0.43)ViewN/AView Earnings Details
2/25/2016Q1($0.4750)$0.04$0.05 millionViewListenView Earnings Details
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details
6/6/2014($0.44)$0.39ViewN/AView Earnings Details
4/30/2014($0.44)$0.39$7.01 millionViewN/AView Earnings Details
2/25/2014Q4 2013($0.50)($0.50)ViewN/AView Earnings Details
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details
7/22/2013Q2 2013($0.44)($0.40)ViewN/AView Earnings Details
5/2/2013Q1 2013($0.45)($0.30)ViewN/AView Earnings Details
2/19/2013Q4 2012($0.44)($0.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

RedHill Biopharma (NASDAQ:RDHL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

RedHill Biopharma (NASDAQ RDHL) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 20.03%
Insider Trading History for RedHill Biopharma (NASDAQ:RDHL)
Insider Trading History for RedHill Biopharma (NASDAQ:RDHL)

RedHill Biopharma (NASDAQ RDHL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

RedHill Biopharma (NASDAQ RDHL) News Headlines

Source:
DateHeadline
RedHill Biopharma Ltd (RDHL) Receives Consensus Rating of "Buy" from AnalystsRedHill Biopharma Ltd (RDHL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 19 at 1:35 AM
Redhill (RDHL) Analyst And Investor Webcast On RHB-104 For Crohns Disease - SlideshowRedhill (RDHL) Analyst And Investor Webcast On RHB-104 For Crohn's Disease - Slideshow
seekingalpha.com - May 17 at 9:21 AM
RedHill Biopharma Ltd (RDHL) to Post Q3 2018 Earnings of ($0.44) Per Share, Seaport Global Securities ForecastsRedHill Biopharma Ltd (RDHL) to Post Q3 2018 Earnings of ($0.44) Per Share, Seaport Global Securities Forecasts
www.americanbankingnews.com - May 17 at 6:54 AM
RedHill Biopharma Ltd (RDHL) to Post Q2 2018 Earnings of ($0.46) Per Share, Seaport Global Securities ForecastsRedHill Biopharma Ltd (RDHL) to Post Q2 2018 Earnings of ($0.46) Per Share, Seaport Global Securities Forecasts
www.americanbankingnews.com - May 16 at 7:27 AM
Zacks: Brokerages Anticipate RedHill Biopharma Ltd (RDHL) Will Announce Quarterly Sales of $2.65 MillionZacks: Brokerages Anticipate RedHill Biopharma Ltd (RDHL) Will Announce Quarterly Sales of $2.65 Million
www.americanbankingnews.com - May 16 at 1:42 AM
RedHill Biopharmas (RDHL) CEO Dror Ben-Asher on Q1 2018 Results - Earnings Call TranscriptRedHill Biopharma's (RDHL) CEO Dror Ben-Asher on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 9:43 AM
RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohns Disease on May 15RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn's Disease on May 15
globenewswire.com - May 15 at 9:43 AM
 Brokerages Anticipate RedHill Biopharma Ltd (RDHL) to Post -$0.48 Earnings Per Share Brokerages Anticipate RedHill Biopharma Ltd (RDHL) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - May 14 at 11:12 PM
RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15
finance.yahoo.com - May 14 at 10:40 AM
RedHill Biopharma (RDHL) Upgraded at Zacks Investment ResearchRedHill Biopharma (RDHL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:23 PM
HC Wainwright Analysts Give RedHill Biopharma (RDHL) a $36.00 Price TargetHC Wainwright Analysts Give RedHill Biopharma (RDHL) a $36.00 Price Target
www.americanbankingnews.com - May 9 at 5:12 PM
RedHill Biopharma (RDHL) Issues Quarterly  Earnings ResultsRedHill Biopharma (RDHL) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 4:34 PM
BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary ShareBRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share
www.reuters.com - May 9 at 9:15 AM
RedHill Biopharma (RDHL) Downgraded to Strong Sell at ValuEngineRedHill Biopharma (RDHL) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM
Durham pharma eyes potential approval of drug in roughly $5B marketDurham pharma eyes potential approval of drug in roughly $5B market
finance.yahoo.com - May 7 at 4:46 PM
BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohns Disease TrialBRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial
www.reuters.com - May 7 at 9:52 AM
RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohns ...RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn's ...
globenewswire.com - May 7 at 9:52 AM
RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s DiseaseRedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease
finance.yahoo.com - May 7 at 9:52 AM
RedHill Biopharma (RDHL) Upgraded at ValuEngineRedHill Biopharma (RDHL) Upgraded at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018
finance.yahoo.com - May 1 at 9:07 AM
$2.14 Million in Sales Expected for RedHill Biopharma Ltd (RDHL) This Quarter$2.14 Million in Sales Expected for RedHill Biopharma Ltd (RDHL) This Quarter
www.americanbankingnews.com - April 29 at 4:04 AM
Zacks: Analysts Expect RedHill Biopharma Ltd (RDHL) to Announce -$0.57 EPSZacks: Analysts Expect RedHill Biopharma Ltd (RDHL) to Announce -$0.57 EPS
www.americanbankingnews.com - April 27 at 9:59 AM
RedHill Biopharma Ltd (RDHL) Receives Average Rating of "Buy" from AnalystsRedHill Biopharma Ltd (RDHL) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 24 at 1:30 AM
Zacks: Brokerages Anticipate RedHill Biopharma Ltd (RDHL) Will Announce Quarterly Sales of $2.14 MillionZacks: Brokerages Anticipate RedHill Biopharma Ltd (RDHL) Will Announce Quarterly Sales of $2.14 Million
www.americanbankingnews.com - April 12 at 3:52 AM
Redhill (RDHL) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowRedhill (RDHL) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:40 PM
-$0.57 EPS Expected for RedHill Biopharma Ltd (RDHL) This Quarter-$0.57 EPS Expected for RedHill Biopharma Ltd (RDHL) This Quarter
www.americanbankingnews.com - April 10 at 11:12 AM
Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, SReport: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, S
www.nasdaq.com - April 10 at 9:29 AM
RedHill revenues up 31 percent in Q4RedHill revenues up 31 percent in Q4
finance.yahoo.com - April 9 at 4:43 PM
BRIEF-Swire Pacific Announces Sale Of Residential Unit For HK$120 Million By Redhill PropertiesBRIEF-Swire Pacific Announces Sale Of Residential Unit For HK$120 Million By Redhill Properties
finance.yahoo.com - April 9 at 9:42 AM
RedHill Biopharma Provides Semi-Annual Business UpdateRedHill Biopharma Provides Semi-Annual Business Update
finance.yahoo.com - April 9 at 9:42 AM
RedHill Biopharma Ltd (RDHL) Receives Consensus Recommendation of "Buy" from BrokeragesRedHill Biopharma Ltd (RDHL) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 30 at 1:32 AM
RedHill Biopharma announces Bekinda presentations in acute gastroenteritis at SAEM 2018RedHill Biopharma announces Bekinda presentations in acute gastroenteritis at SAEM 2018
seekingalpha.com - March 28 at 4:38 PM
RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM ...RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM ...
globenewswire.com - March 27 at 4:46 PM
RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual MeetingRedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting
finance.yahoo.com - March 27 at 9:11 AM
RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-DRedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D
finance.yahoo.com - March 26 at 10:08 AM
 Analysts Expect RedHill Biopharma Ltd (RDHL) Will Announce Earnings of -$0.57 Per Share Analysts Expect RedHill Biopharma Ltd (RDHL) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - March 24 at 11:28 AM
RedHill Biopharma to Present at HC Wainwright Annual Global Life Sciences Conference - GlobeNewswire (press release)RedHill Biopharma to Present at HC Wainwright Annual Global Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:46 AM
RedHill Biopharma (RDHL) Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at AACRRedHill Biopharma (RDHL) Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at AACR
www.streetinsider.com - March 20 at 9:14 AM
RedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences ConferenceRedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 20 at 9:14 AM
RedHill Biopharma (RDHL) Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at ... - StreetInsider.comRedHill Biopharma (RDHL) Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at ... - StreetInsider.com
www.streetinsider.com - March 19 at 10:00 AM
RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual MeetingRedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting
finance.yahoo.com - March 19 at 10:00 AM
RedHill Biopharma Ltd - (RDHL) Expected to Post Quarterly Sales of $2.14 MillionRedHill Biopharma Ltd - (RDHL) Expected to Post Quarterly Sales of $2.14 Million
www.americanbankingnews.com - March 9 at 2:29 PM
RedHill Biopharma Ltd - (RDHL) Given Consensus Rating of "Buy" by BrokeragesRedHill Biopharma Ltd - (RDHL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM
RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor UpdateRedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update
finance.yahoo.com - February 22 at 9:11 AM
$1.89 Million in Sales Expected for RedHill Biopharma Ltd - (RDHL) This Quarter$1.89 Million in Sales Expected for RedHill Biopharma Ltd - (RDHL) This Quarter
www.americanbankingnews.com - February 20 at 4:32 AM
RedHill Biopharma (RDHL) Scheduled to Post Earnings on ThursdayRedHill Biopharma (RDHL) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 15 at 3:14 AM
RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018 - GlobeNewswire (press release)RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018 - GlobeNewswire (press release)
globenewswire.com - February 14 at 6:37 AM
RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018
finance.yahoo.com - February 13 at 3:24 PM
RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018
finance.yahoo.com - February 13 at 3:24 PM
RedHill Biopharma Ltd - (RDHL) Given Average Rating of "Buy" by AnalystsRedHill Biopharma Ltd - (RDHL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 8 at 1:32 AM

SEC Filings

RedHill Biopharma (NASDAQ:RDHL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

RedHill Biopharma (NASDAQ:RDHL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

RedHill Biopharma (NASDAQ RDHL) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.